Alembic (ALEMBICLTD) Share News & Alerts
Every article that mentions ALEMBICLTD is analysed by our AI, which assigns a sentiment and tracks the actual price move after the alert fires.
Alembic slides as Q4 PAT tanks 60% YoY to Rs 10 cr
▼ Bearish +0.34%
The stock is likely to experience a bearish trend over a 1-to-2-week swing trading timeframe due to a significant 60% drop in its core standalone net profit after tax. Although consolidated figures were stabilized by associate profits, the deterioration in core standalone earnings and operating margins signals immediate operational headwinds that will likely trigger near-term portfolio liquidations by positional traders.
Alembic Pharma gains after receiving USFDA nod for Darolutamide tablets
▲ Bullish +1.04%
The USFDA approval for Darolutamide tablets (a generic version of the blockbuster drug Nubeqa) opens a high-value therapeutic market for Alembic Pharma. Given the drug's 46% risk reduction in clinical trials and its status as a cornerstone for prostate cancer therapy, this approval provides a clear revenue catalyst for the company. For a swing or positional trader, this represents a fundamental 'moat' expansion that can lead to multi-day accumulation as analysts re-rate the stock's US earnings potential.
Get real-time alerts for ALEMBICLTD
Add ALEMBICLTD to your portfolio and receive instant AI-powered news alerts on your phone.
Set up free alerts →Explore More
AI Technical Analysis Alert History Other Bullish Stocks Today’s Trending